Previous 10 | Next 10 |
Ironwood Pharmaceuticals (NASDAQ: IRWD ) : Q2 Non-GAAP EPS of $0.16 beats by $0.06 ; GAAP EPS of $0.16 beats by $0.08 . More news on: Ironwood Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
– Grew LINZESS ® (Iinaclotide) total prescription demand by 9% year-over-year; new-to-brand prescription demand grew >15% in June 2020 compared to March 2020 – – Made important updates designed to strengthen IW-3718 Phase III program; FDA indicated that...
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its second quarter 2020 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 6, 2020. Individuals interested in participating in the call should dial (866) 324-3683 (U.S. and Cana...
Ironwood Pharmaceuticals (NASDAQ: IRWD ) has reached alignment with the FDA on certain updates to its Phase III clinical program evaluating IW-3718 in adults with refractory gastroesophageal reflux disease (GERD). More news on: Ironwood Pharmaceuticals, Inc., Healthcare stocks new...
– Changed primary endpoint to continuous from current responder endpoint, in-line with recent FDA guidance and very similar to IW-3718 Phase IIb trial – – Conducting early assessment of IW-3718-302, one of two identical Phase III trials; expect to report outcome of...
Zynerba Reports Positive Top Line Results from Autism Study Zynerba Pharmaceuticals Inc. ( ZYNE ) announced encouraging results from its Phase 2 BRIGHT trial. The study aimed to evaluate the safety, tolerability and efficacy of the drug candidate in pediatric and adolescent patients with a...
A Phase II trial evaluating Ironwood Pharmaceuticals' (NASDAQ: IRWD ) MD-7246 in adult patients with abdominal pain associated with irritable bowel syndrome with diarrhea (IBS-D) failed to achieve its primary or key secondary endpoints. More news on: Ironwood Pharmaceuticals, Inc., ...
– Trial did not achieve statistically significant improvements in abdominal pain relative to placebo – – Companies plan to discontinue development of MD-7246 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today annou...
The following slide deck was published by Ironwood Pharmaceuticals, Inc. in conjunction with their 2020 Q1 earnings Read more ...
Image source: The Motley Fool. Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Q1 2020 Earnings Call May 7, 2020 , 11:00 p.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 8, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...